Pharmacokinetics of cysteamine bitartrate following gastrointestinal infusion

British Journal of Clinical Pharmacology

Volumn 63, Issue 1, 2007, Pages 36-40

  Fidler, Meredith C ^a   Barshop, Bruce A ^a   Gangoiti, Jon A ^a   Deutsch, Reena ^a   Martin, Michael ^a   Schneider, Jerry A ^a   Dohil, Ranjan ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCSD MEDICAL CENTER   (United States)

Author keywords

Plasma cysteamine; Tandem mass spectrometry

Indexed keywords

MERCAPTAMINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG INFUSION; DRUG MECHANISM; FEMALE; HUMAN; HUMAN EXPERIMENT; INTESTINE ABSORPTION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NASOGASTRIC TUBE; NORMAL HUMAN; PRIORITY JOURNAL; REPEATED DRUG DOSE; STOMACH ABSORPTION;

ADULT; AREA UNDER CURVE; CYSTEAMINE; CYSTINOSIS; FEMALE; HUMANS; INTESTINAL ABSORPTION; MALE; NOOTROPIC AGENTS; PROSPECTIVE STUDIES;

EID: 33845410994     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02734.x     Document Type: Article

References (21)

1. Gahl WA, Thoene JG, Schneider JA. Cystinosis. N Engl J Med 2002; 347: 111-21.
2. Pisoni RL, Thoene JG, Christensen HN. Detection and characterization of carrier-mediated cationic amino acid transport in lysosomes of normal and cystinotic human fibroblasts. Role in therapeutic cystine removal? J Biol Chem 1985; 260: 4791-8.
3. Kimonis VE, Troendle J, Rose SR, Yang ML, Markello TC, Gahl WA. Effects of early cysteamine therapy on thyroid function and growth in nephropathic cystinosis. J Clin Endocrinol Metab 1995; 80: 3257-61.
4. Markello TC, Bernardini IM, Gahl WA. Improved renal function in children with cystinosis treated with cysteamine. N Engl J Med 1993; 328: 1157-62.
5. Gahl WA, Reed GF, Thoene JG, Schulman JD, Rizzo WB, Jonas AJ, Denman DW, Schlesselman JJ, Corden BJ, Schneider JA. Cysteamine therapy for children with nephropathic cystinosis. N Engl J Med 1987; 316: 971-7.
6. Gentile V, Cooper AJ. Transglutaminases - possible drug targets in human diseases. Curr Drug Targets CNS Neurol Disord 2004; 3: 99-104.
7. Van Raamsdonk JM, Pearson J, Bailey CD, Bailey CDC, Rogers DA, Johnson GVW, Hayden MR, Leavitt BR. Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. J Neurochem 2005; 95: 210-20.
8. Fox JH, Barber DS, Singh B, Zucker B, Swindell MK, Norflus F, Buzescu R, Chopra R, Ferrante RJ, Kazantsev A, Hersch SM. Cystamine increases 1-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation. J Neurochem 2004; 91: 413-22.
9. Lesort M, Lee M, Tucholski J, Johnson GV. Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. J Biol Chem 2003; 278: 3825-30.
10. Dedeoglu A, Kubilus JK, Jeitner TM, Matson SA, Bogdanov M, Kowall NW, Matson WR, Cooper AJ, Ratan RR, Beal MF, Hersch SM, Ferrante RJ. Therapeutic effects of cystamine in a murine model of Huntington's disease. J Neurosci 2002; 22: 8942-50.
11. Junn E, Ronchetti RD, Quezado MM, Kim SY, Mouradian MM. Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A 2003; 100: 2047-52.
12. Dohil R, Newbury RO, Sellers ZM, Deutsch R, Schneider JA. The evaluation and treatment of gastrointestinal disease in children with cystinosis receiving cysteamine. J Pediatr 2003; 143: 224-30.
13. Dohil R, Fidler M, Barshop B, Newbury RO, Sellers ZM, Deutsch R, Schneider JA. Esomeprazole therapy for gastric acid hypersecretion in children with cystinosis. Pediatr Nephrol 2005; 20: 1786-93.
14. Guan XHG, Dwivedi C, Matthees DP. A simultaneous liquid chromatography/mass spectrometric assay of glutathione, cysteine, homecysteine and their disulfides in biological samples. J Pharmaceut Biomed Anal 2003; 31: 251-61.
15. Schneider JA. Approval of cysteamine for patients with cystinosis. Pediatr Nephrol 1995; 9: 254.
16. Gretz NMF, Augustin R, Barrat TM, Bender-Gotze C, Brandis M, Bremer HJ. Survival time in cystinosis. A collaborative study. Proc Eur Dial Transplant Assoc 1983; 19: 582-9.
17. Thoene JG, Oshima RG, Crawhall JC, Olson DL, Schneider JA. Cystinosis. Intracellular cystine depletion by aminothiols in vitro and in vivo. J Clin Invest 1976; 58: 180-9.
18. Pinto JT, Van Raamsdonk JM, Leavitt BR, Hayden MR, Jeitner TM, Thaler HT, Krasnikov BF, Cooper AJ. Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease. J Neurochem 2005; 94: 1087-101.
19. Dubinsky R, Gray CCYTE-I-HD. Phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington's disease. Mov Disord 2005 October 28 (Epub ahead of print).
20. Tremblay ME, Saint-Pierre M, Bourhis E, Levesque D, Rouillard C, Cicchetti F. Neuroprotective effects of cystamine in aged parkinsonian mice. Neurobiol Aging 2005 May 20 (Epub ahead of print).
21. Dohil R, Fidler M, Barshop BA, Martin M, Gangoiti J, Deutsch R, Schneider JA. Understanding intestinal cysteamine absorption. J Pediatr 2006; 148: 764-9.